Entry |
|
Name |
Desloratadine (JAN/USP/INN); Clarinex (TN) |
Product |
|
Generic |
|
Formula |
C19H19ClN2
|
Exact mass |
310.1237
|
Mol weight |
310.8206
|
Structure |

|
Simcomp |
|
Class |
Anti-allergic agent
DG01557 Histamine receptor antagonist
DG01482 Histamine receptor H1 antagonist
|
Remark |
Therapeutic category: | 4490 |
Product (mixture): | D10850<US> |
|
Efficacy |
Antiallergic, Antipruritic, H1 receptor antagonist |
Disease |
|
Comment |
Treatment of seasonal allergic rhinitis
|
Target |
|
Pathway |
hsa04080 | Neuroactive ligand-receptor interaction |
hsa04750 | Inflammatory mediator regulation of TRP channels |
|
Interaction |
|
Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
R RESPIRATORY SYSTEM
R06 ANTIHISTAMINES FOR SYSTEMIC USE
R06A ANTIHISTAMINES FOR SYSTEMIC USE
R06AX Other antihistamines for systemic use
R06AX27 Desloratadine
D03693 Desloratadine (JAN/USP/INN) <JP/US>
USP drug classification [BR:br08302]
Respiratory Tract/Pulmonary Agents
Antihistamines
Histamine (H1) Receptor Antagonists, Mildly/Non-sedating
Desloratadine
D03693 Desloratadine (JAN/USP/INN)
Therapeutic category of drugs in Japan [BR:br08301]
4 Agents affecting cellular function
44 Allergic agents
449 Miscellaneous
4490 Miscellaneous
D03693 Desloratadine (JAN/USP/INN)
Target-based classification of drugs [BR:br08310]
G Protein-coupled receptors
Rhodopsin family
Histamine
HRH1
D03693 Desloratadine (JAN/USP/INN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D03693
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D03693
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D03693
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D03693
|
Other DBs |
|
LinkDB |
|
KCF data |
ATOM 22
1 C1x C 15.9600 -18.2700
2 C8y C 15.1200 -17.1500
3 C8y C 15.4000 -15.7500
4 C2y C 16.7300 -15.1900
5 C1x C 17.3600 -18.2700
6 C8y C 17.9200 -15.8200
7 C8y C 18.2700 -17.2200
8 C8x C 14.4200 -14.8400
9 C8x C 13.0900 -15.1900
10 C8y C 12.7400 -16.5900
11 C8x C 13.7200 -17.5000
12 C8x C 19.6000 -17.6400
13 C8x C 20.6500 -16.7300
14 C8x C 20.3700 -15.3300
15 N5x N 18.9700 -14.9100
16 C2y C 16.7300 -13.7900
17 X Cl 11.3979 -16.9886
18 C1x C 17.9424 -13.0900
19 C1x C 17.9424 -11.6900
20 N1x N 16.7300 -10.9900
21 C1x C 15.5176 -11.6900
22 C1x C 15.5176 -13.0900
BOND 25
1 3 4 1
2 1 5 1
3 4 6 1
4 2 3 1
5 5 7 1
6 1 2 1
7 6 7 1
8 3 8 2
9 8 9 1
10 9 10 2
11 10 11 1
12 2 11 2
13 7 12 2
14 12 13 1
15 13 14 2
16 14 15 1
17 6 15 2
18 4 16 2
19 10 17 1
20 16 18 1
21 18 19 1
22 19 20 1
23 20 21 1
24 21 22 1
25 16 22 1
|